Abstract: Disclosed is a new vector for pharmacologically active water-insoluble molecules. These nanovectors, which are in the form of carbon nanoplatforms, are capable of solubilising the active molecules while reducing the side effects of the treatments. Also disclosed are the processes for synthesizing these nanoplatforms, as well as to the use thereof as a drug, particularly in the treatment of brain tumors.

Abstract: The present invention provides use of EB1 as a biomarker for predicting the response of a brain neoplasm to a compound of formula (I) wherein R represents phenyl or pyridinyl; wherein phenyl is optionally substituted by one or two substituents independently selected from lower alkyl, lower alkoxy, amino, acetylamino, halogen and nitro; and wherein pyridinyl is optionally substituted by amino or halogen; R1 represents hydrogen or cyano-lower alkyl; or a pharmaceutically acceptable derivative thereof, and wherein the prefix lower denotes a radical having up to and including a maximum of 4 carbon atoms; in particular wherein a higher level of EB1 in the sample from the subject relative to a standard value or set of standard values predicts sensitivity of the brain neoplasm to the compound of formula I or pharmaceutically acceptable derivative thereof. The invention also provides methods of treatment and kits for use according to the invention.